Page last updated: 2024-09-05

cilengitide and cediranib

cilengitide has been researched along with cediranib in 3 studies

Compound Research Comparison

Studies
(cilengitide)
Trials
(cilengitide)
Recent Studies (post-2010)
(cilengitide)
Studies
(cediranib)
Trials
(cediranib)
Recent Studies (post-2010) (cediranib)
19429133279102204

Protein Interaction Comparison

ProteinTaxonomycilengitide (IC50)cediranib (IC50)
Platelet-derived growth factor receptor betaHomo sapiens (human)0.005
Fibroblast growth factor receptor 1Homo sapiens (human)0.026
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.036
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.005
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.003
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0016

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stupp, R; Tabatabai, G1
Ahluwalia, MS; Batchelor, TT; Duda, DG; Gerstner, ER; Grossman, S; Jain, RK; Kaley, TJ; Levine, MA; Mikkelsen, T; Nabors, BL; Olson, JJ; Wen, PY; Ye, X1
Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D1

Reviews

1 review(s) available for cilengitide and cediranib

ArticleYear
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
    Der Nervenarzt, 2010, Volume: 81, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Glioma; Humans; Microcirculation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Snake Venoms; Vascular Endothelial Growth Factor A

2010

Trials

1 trial(s) available for cilengitide and cediranib

ArticleYear
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Neuro-oncology, 2015, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Snake Venoms; Treatment Outcome; Young Adult

2015

Other Studies

1 other study(ies) available for cilengitide and cediranib

ArticleYear
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
    International journal of radiation oncology, biology, physics, 2018, 05-01, Volume: 101, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmustine; Chemoradiotherapy; Dasatinib; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Photons; Progression-Free Survival; Propensity Score; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Snake Venoms; Supratentorial Neoplasms; Temozolomide; Young Adult

2018